Finoriq research workspace
Aldeyra Therapeutics, Inc. (ALDX) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Aldeyra Therapeutics, Inc. (ALDX).
Company Snapshot
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- Company
- Aldeyra Therapeutics, Inc. (ALDX)
- Ticker
- ALDX
- Market Cap
- $104.1M
- Latest Price
- $1.725
- Industry
- Biotech & Pharma
Aldeyra Therapeutics, Inc. (ALDX) Recent Insider Transactions
Recent market insider transaction records indexed for Aldeyra Therapeutics, Inc. (ALDX).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| DOUGLAS RICHARDCommon Stock | P | Acquired | $98,000 | 2026-03-19 |
| Alfieri MichaelPrincipal Financial Officer | P | Acquired | $7,100 | 2026-03-18 |
| Alfieri MichaelPrincipal Financial Officer | P | Acquired | $13,250 | 2025-08-13 |
| Machatha StephenChief Development Officer | S | Disposed | -$113,713 | 2025-08-11 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.